Ginefiv S.L.
- Address
- lock Available on a paid plan
Ovarian Stimulation Strategies
At Ginefiv S.L. the focus is on improving outcomes for women facing female infertility and those undergoing assisted reproductive technologies. Current studies compare different pituitary suppression methods during double ovarian stimulation to increase the number of euploid embryos for preimplantation genetic testing.
- Progestin‑primed ovarian stimulation (PPOS) vs GnRH antagonist protocols
- Double ovarian stimulation (DUOSTIM) with embryo accumulation
- Use of FE 999302 in combination with follitropin delta
- Timing variations of FE 999302 during controlled ovarian stimulation
These investigations aim to refine stimulation regimens, enhance embryo quality, and expand treatment options for patients indicated for IVF/ICSI.
Uterine Contractility and Implantation
Research at the clinic also explores how uterine activity influences implantation success in women undergoing IVF. An exploratory trial evaluates the effects of nolasiban on uterine contractility and its potential to improve pregnancy outcomes.
- Pharmacodynamics of nolasiban dosing regimens
- Impact of reduced uterine contractility on embryo implantation
- Safety profile of nolasiban in IVF cycles
- Potential integration of nolasiban with standard IVF protocols
By targeting uterine contractility, the studies hope to reduce implantation failure and support healthier pregnancies for those with pregnancy complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Ginefiv S.L.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ferring Pharmaceuticals A/S3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ginefiv S.L.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the ovarian response after controlled ovarian stimulation with mixed protocols of follitropin delta (REKOVELLE) and highly purified human menopausal gonadotropin (MENOPUR) in women undergoing an assisted reproductive technology programme | Ferring Pharmaceuticals A/S | Phase I | Not Recruiting | — | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ganirelix | 2 | Unknown | 2024-12-05 | 2024-12-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.